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Introduction: While many of the commonly used conservative treatments for knee osteoarthritis (OA) have been
recognized to be effective, there is still insufficient evidence available. Among the pharmacological treatments for knee
OA, oral non-steroidal anti-inflammatory drugs (NSAIDs) act rapidly and are recommended for the management of OA.
However, frequent and serious adverse effects of NSAIDs have been recognized. Intra-articular injections of hyaluronic
acid (IA-HA) for the treatment of knee OA have been shown to reduce pain and improve joint function. However, there
has been no qualified direct comparison study of the efficacy and safety between IA-HA and NSAIDs for patients with
knee OA. The aim of this study was to clarify the efficacy and safety of early-phase IA-HA in comparison to those of
NSAIDs for patients with knee OA.
Methods: This multicenter, randomized, open-label, parallel-group, non-inferiority comparison study with an oral NSAID
involved a total of 200 patients with knee OA. An independent, computer-generated randomization sequence was used
to randomly assign patients in a 1:1 ratio to NSAIDs three times per day for five weeks (n = 100) or IA-HA once a week for
five weeks (n = 100). The primary endpoint was the percentage change in the patient-oriented outcome measure for knee
OA, the Japanese Knee Osteoarthritis Measure (JKOM) score. All patients were questioned regarding any adverse events
during treatment. The full analysis set (FAS) was used for analysis. The margin of non-inferiority was 10%.
Results: The analyses of primary endpoint included 98 patients in the IA-HA group and 86 patients in the NSAID group.
The difference in the percentage changes of the JKOM score between the two intervention arms (IA-HA; -34.7%
(P<0.001), NSAID; -32.2% (P<0.001)) was −2.5% (95% confidence interval (CI): -14.0 to 9.1), indicating IA-HA was not
inferior to NSAID. The frequency of both withdrawal and adverse events in the IA-HA group were significantly lower
than those in the NSAID group (P = 0.026 and 0.004, respectively).
Conclusions: The early efficacy of IA-HA is suggested to be not inferior to that of NSAIDs, and that the safety of the
early phase of IA-HA is superior to that of NSAIDs for patients with knee OA.
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Osteoarthritis (OA) is an increasingly important public-
health problem [1]. The total societal cost of the treatment
of OA has been estimated to increase worldwide because
of its dramatic growth in morbidity [2]. The current treat-
ment for knee OA consists of conservative treatment, such
as exercise, physical therapy, pharmacological agents and,
in some cases, surgical treatment [3,4]. While many of the
commonly used conservative treatments have been recog-
nized to be effective [5], there is still insufficient evidence
available.
Among the pharmacological treatments for knee OA,
oral non-steroidal anti-inflammatory drugs (NSAIDs) act
rapidly and are recommended for the management of OA,
although frequent and serious adverse effects of NSAIDs
have been recognized [5]. Hyaluronic acid (HA) is a nat-
ural constituent of joint fluid. Intra-articular injections of
HA (IA-HA) for the treatment of knee OA have been
shown to reduce the pain and improve joint function [5-7].
Although IA-HA is also recommended, it acts relatively
slowly and there was considerable heterogeneity in the out-
comes between trials [8-11]. In addition, there has been
no qualified direct comparison study of efficacy and safety
between IA-HA and NSAIDs for patients with knee OA.
The aim of this multicenter, randomized, parallel-group,
open-label, non-inferiority trial was to compare the early
efficacy and safety of IA-HA and NSAIDs in patients with
knee OA.
Methods
Study design and participants
The trial was planned by the Cartilage Metabolism
Research Group, consisting mainly of Japanese orthope-
dists, to clarify the early efficacy and safety of IA-HA (high
molecular weight 2,700 kDa HA, Chugai Pharmaceutical
Co. Ltd., Tokyo, Japan) in comparison to an NSAID (loxo-
profen sodium, Daiichi Sankyo Pharmaceuticals Co. Ltd.,
Tokyo, Japan), in a multicenter, randomized, open-
label, parallel-group, non-inferiority trial. The protocol
was reviewed and approved by the ethics committee
of Juntendo University, Tokyo, Japan, and was also
reviewed by the institutional review board of each par-
ticipating institution. This study was undertaken at 20
hospitals throughout Japan between February, 2008 and
December, 2010 (see Acknowledgements), in accordance
with the Declaration of Helsinki, and with the Ethical
Guidelines for Clinical Studies of the Japanese Ministry of
Health, Labor, and Welfare. This trial was registered at
UMIN-CTR [12], UMIN000001026.
Subjects
All patients provided written informed consent before
enrollment in this trial. The inclusion criteria for the
present study included (1) subjects who were able to walkwith painful knee OA and fulfilled the criteria for knee
OA of the medial femorotibial joint as defined by the
American College of Rheumatology (ACR) [13], (2) the
age of the subjects ranged from 50 to 80, (3) female sub-
jects were required to be postmenopausal, and (4) all sub-
jects had radiographic knee OA with Kellgren-Lawrence
(K/L) grade 1 to 3 [14] evaluated by the weight-bearing
anteroposterior X-rays of the tibiofemoral joint using the
bilateral standing extended view.
The exclusion criteria included (1) patients who had re-
ceived either an oral, topical or intra-articular steroid dur-
ing the four weeks before the study, (2) patients who had
received IA-HA within four weeks before the study, (3) pa-
tients who had received either an oral, topical or supposi-
tory NSAID within two weeks before the study, (4) patients
who had secondary knee OA, (5) patients with patellofe-
moral OA with a K/L grade of 3 or higher, (6) patients with
severe OA (K/L grade 3 or higher) in a location other than
the knee joint, (7) patients with rheumatoid arthritis, (8) pa-
tients who had received joint replacement surgery in either
knee or/and a hip, (9) patients who had allergies to either
HA or NSAIDs, (10) patients who had either hematological,
cardiac, hepatic or renal disorders, (11) patients who had
experienced an asthma attack induced by NSAIDs, and
(12) patients whom the physician recognized as not suitable
for enrollment in the study for other reasons.
Randomization and masking
A centralized, computer-generated randomization was
conducted to randomly assign patients in a 1:1 ratio to the
IA-HA or NSAID groups. Investigators were masked to as-
signment before, but not after, randomization. The website
for patient registration and randomization was prepared
and controlled by the coordinating data center (Gunma
University, Maebashi, Japan). The blocked randomization
was stratified by the participating medical center and the
K/L grade of knee OA.
Treatment procedures
A total of 200 patients with symptomatic knee OA were
registered from 20 hospitals and randomized for treat-
ment with the NSAID or IA-HA, as described above.
For patients treated with the NSAID, they received
three daily 60 mg NSAID tablets (total 180 mg)/day,
one after each meal, for five weeks. Additional use of
gastro-protective drugs, such as a proton pump inhibi-
tor (PPI), in combination with the NSAID was allowed
for those in the NSAID group. For patients treated with
IA-HA, an intra-articular injection of high-molecular-
weight 2,700 kDa HA (25 mg) was administered into
the affected joint five times, at weekly intervals in the
morning. Concomitant use of other drugs for the treat-
ment of OA and drugs that affect bone and cartilage
metabolism were not allowed during the trial.
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and safety
The patients were evaluated for their (1) baseline char-
acteristics, (2) radiographic analysis of the knee, (3)
compliance with the treatment, (4) clinical manifesta-
tions, and (5) safety.Evaluation of the response to treatment (efficacy)
Pain was evaluated by a visual analog scale (VAS, 0 to 100).
The clinical manifestations were evaluated by the Japanese
Knee Osteoarthritis Measure (JKOM) score [15]. The
JKOM is a patient-based, self-answered evaluation score
that includes four subcategories: pain and stiffness (0 to
32), activities of daily living (0 to 40), social activities (0 to
20), and general health conditions (0 to 8) with 100 points
as the maximum score. The JKOM score is higher in pa-
tients with more pain and physical disability, and this evalu-
ation modality is considered to have sufficient reliability
and validity for studies of the clinical outcomes of Japanese
subjects with knee OA [15]. The measure has also been
shown to have reliability and validity by means of statistical
evaluation and comparison with other health-related scales,
such as the Western Ontario and McMaster Universities
Arthritis Index (WOMAC) and the Medical Outcomes
Study 36-Item Short-Form Health Survey (SF-36) [15].
The primary endpoint was to compare the percentage
change from baseline in the JKOM score at five weeks.
The secondary endpoint was to compare the percentage
change from baseline in the pain VAS score.
The definition of a response to treatment was made fol-
lowing the criteria defined by the Outcome Measures in
Rheumatology Clinical Trials (OMERACT) and Osteoarth-
ritis Research Society International (OARSI) [16]. This
measure consists of both absolute and relative changes in
scales, including both pain and function, to evaluate the af-
fected knee. Relative change means the percentage of
change during the study (final minus baseline over base-
line × 100), whereas absolute change indicates the abso-
lute change during the study (final minus baseline on an
interval scale of 0 to 100). Before assessing patients based
on this scale, we partly modified it for this study by using
the JKOM score, as already reported [17,18]. The response
was defined as relief of joint pain or improvement in func-
tion (at least 50% reduction of the score) and a decrease of
at least 20 mm on the VAS, or clinical improvement meet-
ing at least two of the following three conditions: a de-
crease in joint pain of at least 20% and at least 10 mm on
the VAS; an improvement in function of at least 20% and
a decrease of at least 4 points from a total 40 points (equal
to an absolute change of 10%) on the JKOM functional
subcategory scale; and a decrease in the patient’s global as-
sessment score by at least 20% and at least 10 points from
a total of 100 on the total JKOM scale.Assessment of adverse events induced according to the
treatment modality (safety)
Safety was monitored by recording all adverse events,
evaluating the laboratory data and assessing vital signs.




The trial was designed to establish whether the symptom-
modified effect of IA-HA was non-inferior to that of
NSAID (Δ10%). The sample size of this non-inferiority trial
was calculated to require a total of 194 patients (97 per
treatment group) based on the results of our pilot study
with a 5% dropout rate, 10% non-inferiority margin, 27%
standard deviation (SD), 5% one-sided alpha level, and
power = 0.8 (pilot study: Toshitaka Nakamura, unpublished
data, 2007). The 10% margin was set as the smallest value
that would be clinically important, assuming a reduction of
30% in the mean percentage change of JKOM score in
patients with both IA-HA and NSAID treatment and a
reduction of 10% those receiving a placebo treatment.
Data analysis
The primary statistical analyses of efficacy and safety were
performed on the full analysis set (FAS), which included
all patients treated at least once. For the primary endpoint
of the study, a two-sided 95% confidence interval (CI) for
the group difference ‘test treatment minus reference treat-
ment’ was calculated for the percentage change from base-
line in the JKOM score as non-inferiority analysis. The
non-inferiority of the test treatment was confirmed if the
upper limit of the CI was ≤margin of non-inferiority delta
(10%). For the secondary endpoint, the group difference
and its 95% CI was calculated for the percentage change
from baseline in the VAS pain score.
Quantitative variables were described using the mean,
standard deviation and range. The efficacy of treatment
was examined by a paired t test for both JKOM score and
pain VAS score. A multiple logistic regression analysis was
used to estimate odds ratios and their 95% CIs between
the IA-HA and NSAID treatments in models adjusted for
age, K/L grade, body mass index (BMI) and the participat-
ing medical centers.
All analyses were performed using the SAS System Re-
lease 9.1 software program (SAS Institute, Cary, NC, USA).
The registration number of this trial is UMIN000001026,
and information on the trial can be found online at [12].Results
Patient baseline characteristics
A flow chart of this trial is shown in Figure 1. When 200
patients were enrolled, half (100) of the patients were
Figure 1 A flow chart of the study. FAS, full analysis set; HA, hyaluronic acid; IA-HA, intra-articular injections of HA; ITT, intention-to-treat; JKOM,
Japanese Knee Osteoarthritis Measure (JKOM); NSAID, non-steroidal anti-inflammatory drug; VAS; visual analog scale.
Table 1 Baseline characteristics of the patients in the study
IA-HA NSAID
(n = 99) (n = 93)
Age (y) Mean (SD) 68.2 (7.1) 68.5 (7.0)
Gender Male 27 22
Female 72 71
BMI Mean (SD) 23.8 (3.4) 24.4 (3.6)
K/L grade 1 16 15
2 48 50
3 35 28
JKOM score (Min:0 - Max:100) Mean (SD) 33.8 (15.8) 31.6 (14.1)
Pain VAS (Min:0 - Max:100) Mean (SD) 60.3 (22.4) 55.1 (21.9)
IA, intra-articular; HA, hyaluronic acid; NSAID, non-steroidal anti-inflammatory
drug; BMI, body mass index; K/L, Kellgren-Laurence grade; JKOM, Japanese
Knee Osteoarthritis Measure; VAS, visual analog scale.
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half allocated into the IA-HA group. Two patients in the
IA-HA group and 14 patients in the NSAID group were
excluded; therefore, the remaining 184 patients were in-
cluded in the analyses of the primary endpoint.
The baseline patient characteristics are shown in
Table 1. No significant statistical differences between
the baseline characteristics of both groups were found.
Efficacy analyses (primary and secondary endpoints)
For the primary endpoint analysis, the JKOM score of the
patients in both the NSAID group and in the IA-HA
group was significantly reduced by the treatment
(P<0.001, Table 2), and the percentage change from
baseline in the JKOM score for the two groups was −32.2%
and −34.7%, respectively. The difference in the percentage
changes of the JKOM score between the two interven-
tion arms (primary endpoint) was −2.5% (95% CI: -14.0
to 9.1%).
In a multiple regression analysis performed taking into
consideration the factors considered to stratify the study
design, the difference in the primary endpoint between the
two intervention arms was also less than 10% (data notshown). These results demonstrate that the IA-HA treat-
ment was non-inferior to the NSAID treatment for the
percentage reduction in the clinical symptoms evaluated
by the JKOM.
For the secondary endpoint analysis, the pain VAS score
of the patients in the NSAID group was significantly
Table 2 Results of the primary endpoint of the study
JKOM score % change of JKOM score
Mean SD P (post vs. pre) Mean (%) SD Difference (%) [IA-HA - NSAID] (95% CI)
IA-HA (n = 98) Pre-treatment 33.8 15.9 <0.001 −34.7 39.6 −2.5 (−14.0 to 9.1)
Post-treatment 21.5 14.6
NSAID (n = 86) Pre-treatment 32.0 14.0 <0.001 −32.2 39.8
Post-treatment 22.0 15.5
The effect of the treatment of either IA-HA or NSAID for the patients with knee OA evaluated by JKOM score (left) and percentage (%) change of JKOM score
(right). A P value less than 0.05 was considered to be significant. JKOM, Japanese Knee Osteoarthritis Measure; IA, intra-articular; HA. hyaluronic acid; NSAID,
non-steroidal anti-inflammatory drug.
Ishijima et al. Arthritis Research & Therapy 2014, 16:R18 Page 5 of 8
http://arthritis-research.com/content/16/1/R18reduced by the treatment (P<0.001, Table 3). The per-
centage change from baseline in the VAS score in the
NSAID group was −36.0%. The pain VAS in the IA-HA
group was also significantly reduced by the treatment,
with a percentage change from baseline in the VAS
score of −41.2% (P<0.001). The difference in the per-
centage changes in the pain VAS score between the two
intervention arms (secondary endpoint) was −5.2%
(95% CI: -23.8 to 13.4%).
Subanalyses
When the patients were divided into two groups (re-
sponders or non-responders) by the OMERACT-OARSI
response criteria [16], 69.7% (69/99) of the patients in IA-
HA group were classified as ‘responders’, while 62.4% re-
sponders were found (58/93) in the NSAID group. Again,
there were no significant differences in the frequency of
‘responders’ between these two groups (P = 0.283).
A multiple logistic regression analysis, which was ad-
justed for age, K/L grade, BMI and the participating med-
ical centers, confirmed the lack of significant differences
in the odds ratio of responders between those who re-
ceived IA-HA treatment and those who received NSAID
treatment (odds ratios: 1.47 (95% CI: 0.761 to 2.83)).
We further investigated whether IA-HA is broadly ef-
fective from very early (K/L grade of 1) to moderate stages
of knee OA (K/L grade of 3) (Table 4). Both IA-HA and
NSAID groups significantly reduced the patient-oriented
outcome measure evaluated by the JKOM score in the pa-
tients with both a K/L grade of 2 and 3. In patients with a
K/L grade of 1, IA-HA treatment also reduced the JKOM
score, but this reduction was not significant (P = 0.058).Table 3 Results of the secondary endpoint of the study
Pain VAS
Mean SD P (post vs. pre)
IA-HA (n = 97) Pre-treatment 60.1 22.4 <0.001
Post-treatment 31.8 24.1
NSAID (n = 85) Pre-treatment 55.5 21.8 <0.001
Post-treatment 31.9 23.9
The effect of the treatment of either IA-HA or NSAID for the patients with knee OA
(right). A P value less than 0.05 was considered to be significant. VAS, visual analog
anti-inflammatory drug.On the other hand, NSAID treatment of this group signifi-
cantly reduced the JKOM score (P = 0.001).Safety analyses
During the five weeks of examination, nine of ninety-nine
patients (9.1%) in the IA-HA group were withdrawn from
the study (one patient’s symptoms improved and eight pa-
tients were lost to follow-up). Nineteen of ninety-three pa-
tients (20.4%) of NSAID group were withdrawn from the
study (five patients experienced side effects, four withdrew
consent, two patient’s symptoms improved, and eight were
lost to follow-up). The frequency of the withdrawal rate in
the IA-HA group was significantly lower than that in the
NSAID group (P = 0.026, Table 5).
Serious adverse events, including gastrointestinal (GI)
hospitalization, were not observed in both groups dur-
ing this study. As one patient complained of stiffness in
the affected knee after injection, the frequency of ad-
verse events in patients treated with the IA-HA was
1.0%. Ten (symptom related to GI tract disorder, seven;
drug allergy, three) of ninety-three patients (10.8%) ex-
hibited adverse events in those treated with the NSAID.
The frequency of adverse events in the IA-HA group
was significantly lower than that of those in NSAID
group (P = 0.004, Table 5).
Discussion
This short-term trial clearly demonstrated that both the
IA-HA at weekly intervals and daily oral NSAID over
five weeks significantly improved both the clinical symp-
toms evaluated by the patient-oriented outcome measure% change of VAS score
Mean (%) SD Difference (%) [IA-HA - NSAID] (95% CI)
−41.2 52.7 −5.2 (−23.8 to 13.4)
−36.0 73.8
evaluated by pain VAS score (left) and percentage (%) change of VAS score
scale; IA, intra-articular; HA, hyaluronic acid; NSAID, non-steroidal
Table 4 JKOM score and percentage change of JKOM score by K/L grade subgroup
JKOM score % change of JKOM score
Mean SD P (post vs. pre) Mean (%) SD Difference (%) [IA-HA - NSAID] (95% CI)
K/L grade 1
IA-HA (n = 15) Pre-treatment 24.8 13.0 0.058 −9.3 78.0 25.7 (−19.3 to 70.7)
Post-treatment 18.7 12.6
NSAID (n = 14) Pre-treatment 35.9 15.4 0.001 −34.9 26.0
Post-treatment 23.4 15.7
K/L grade 2
IA-HA (n = 48) Pre-treatment 33.1 14.7 <0.001 −43.8 27.1 −9.2 (−24.4 to 6.0)
Post-treatment 18.8 12.6
NSAID (n = 45) Pre-treatment 30.8 13.9 <0.001 −34.6 44.9
Post-treatment 20.4 14.5
K/L grade 3
IA-HA (n = 35) Pre-treatment 38.6 17.1 <0.001 −33.1 23.6 −6.2 (−21.6 to 9.3)
Post-treatment 26.4 16.9
NSAID (n = 27) Pre-treatment 31.9 13.6 0.003 −26.9 37.0
Post-treatment 23.7 17.3
A P value less than 0.05 was considered to be significant. JKOM, Japanese Knee Osteoarthritis Measure; IA, intra-articular; HA, hyaluronic acid; NSAID, non-steroidal
anti-inflammatory drug; K/L, Kellgren-Laurence grade.
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differences in the symptom-modifying effects were ob-
served during this short period. In addition, the safety of
the early phase of IA-HA treatment was superior to that
of the NSAID in the patients with knee OA.
HA is a large glycosaminoglycan composed of repeat-
ing disaccharides of glucuronic acid and N-acetyl glucosa-
mine that is naturally present in synovial fluid. Several
protective properties of HA have been reported including
shock absorption, traumatic energy dissipation, protective
coating of the articular cartilage surface, and lubrication
[19]. Numerous clinical trials, meta-analyses and system-
atic reviews have indicated its clinical efficacy for knee OA
[5,9,10,20]. Based on these previous findings, the OARSI
recommendations that were revised in 2010 summarized
the effect size (ES) of IA-HA at 0.60 (95% CI; 0.37, 0.83).
However, as the ES declined to 0.22 (95% CI; -0.11, 0.54)
when only the high-quality trials were selected [5], contro-
versy remains regarding the efficacy of HA in treating
knee OA [8]. A recent meta-analysis concluded that theTable 5 Withdrawal and harmful events during the study
Withdrawn Completed Withdrawn Frequency (%) P
IA-HA (n = 99) 90 9 9.1 0.026
NSAID (n = 93) 74 19 20.4
Harmful events Not occurred Occurred Frequency (%) P
IA-HA (n = 99) 98 1 1.0 0.004
NSAID (n = 93) 83 10 10.8
IA, intra-articular; HA, hyaluronic acid; NSAID, non-steroidal
anti-inflammatory drug.pain reduction by IA-HA is observed later than that of
intra-articular corticosteroids [9]. In addition, the effects
of IA-HA for knee OA pain continued over six months
post-intervention [10]. However, few studies have been
conducted to clarify the early effects and safety of IA-HA
in comparison to those of NSAIDs. The results of this
study clearly indicated that the early efficacy of IA-HA
was not inferior in comparison to that of the NSAID.
A number of HA products with a variety of the molecu-
lar weights, ranging from approximately 600 to 6,000 kDa,
have been developed as IA-HA for the treatment of OA
[8]. The considerable heterogeneity of outcomes between
trials may be due in part to differences in HA products [5].
High-molecular-weight HA (>6,000 kDa) is suggested to
have greater effects in comparison to lower-molecular-
weight HA [8]. On the other hand, the intra-articular injec-
tion of high-molecular-weight HA (>6,000 kDa) showed a
greater frequency of adverse events, such as pain flares,
and hot and swollen knees, which typically occurred 24 to
72 hours after injection [21]. There were no cases of pain-
ful, hot or swollen knees during the study.
The molecular mechanisms underlying the efficacy of
IA-HA for OA remain unclear. OA is frequently associ-
ated with the signs and symptoms of inflammation, in-
cluding joint pain, swelling and stiffness leading to
significant functional impairment and disability [2].
Synovitis plays an important role in inducing the pain,
swelling and stiffness in OA [22], and the severity of
synovitis is well correlated with the JKOM score of
the patients with knee OA [23]. It has recently been
reported that HA inhibits the activities of matrix
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in part, involved in OA cartilage degradation as a result
of their induction by proinflammatory cytokines, such as
interleukin (IL)-1 [19,24-26]. Therefore, HA is specu-
lated to modify the structural damage of joints and the
rate of OA progression in addition to the symptom-
modifying effect [27], although further studies are
required.
In this trial, the early efficacy of IA-HA was compared
with that of NSAID for the treatment of knee OA.
NSAIDs have also been proven to be an effective conser-
vative treatment for knee OA [5]. However, a high inci-
dence of serious GI tract adverse events associated with
the use of oral NSAIDs was also demonstrated in a
population-based cohort study of older patients [28]. In
addition, the hospitalization due to GI tract side effects
in patients receiving non-selective NSAIDs was twice as
high as that in those given the cyclooxygenase (Cox)-2
selective agent, celecoxib, or a non-selective NSAID to-
gether with a PPI [28]. Although a PPI was not routinely
used in addition to the NSAID (loxoprofen sodium) in
this study, no serious GI events were noted.
Since chronic kidney disease (CKD), which is similar
to knee OA, is also a prevalent disease especially in older
populations, knee OA patients with CKD may have a
different risk profile and treatment response than knee
OA patients without CKD. However, as patients with
renal disorders were excluded in the present study, as
described in the Methods section, whether the presence
of CKD has any effect on the efficacy and safety of either
the IA-HA or NASIDs remains unclear.
The efficacy of IA-HA for knee OA has been debated
for over a decade. Although it has been systemically evalu-
ated in meta-analyses, most previous studies have focused
on comparing the findings with either placebo or intra-
articular corticosteroids [9,10,29]. No previous studies
have undertaken a meta-analysis with NSAIDs, which is
one of the most efficacious and widely used treatments for
knee OA [5]. The present study clearly shows that IA-HA
is as effective as continuous NSAID use at five weeks of
treatment, and, in addition, it showed a more favorable
safety profile of IA-HA over NSAIDs for knee OA. The
present study suggests that future randomized trials should
thus be carried out with a longer duration of follow-up and
larger samples, in order to identify optimal knee OA treat-
ment alternatives. Furthermore, it would also be interesting
to evaluate whether any synergistic effect of these two com-
bined treatments exists when they are combined.
The current study does have some limitations. First,
this investigation was an open-label randomized trial
and not a double-blind controlled trial. Therefore, the
design may have introduced certain bias into the results.
Second, the trial’s size was calculated to have sufficient
power to exclude a 10% between-group percentage changeof JKOM score, which can be debated. This margin was
supported by our pilot study, as described previously.
Third, in subgroup analysis for the patients with a K/L
grade of 1, IA-HA treatment reduced the JKOM score.
However, this reduction was not statistically significant
(P = 0.058). Although the reason for this is unclear, the in-
terpretation of the result was limited by the small number
of patients (n = 15) and, therefore, it may be one of the
limitations. Even though some subjects had a K/L grade of
1, some have an increased risk for rapid progression of the
disease [30]. Unfortunately, we cannot predict radiograph-
ically who is at risk for progression [4].
Conclusions
The early efficacy of IA-HA is suggested to be not infer-
ior to that of a NSAID, and the safety of the early phase
of IA-HA is superior to that of a NSAID for patients
with knee OA.
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